Publications en collaboration avec des chercheurs de Hospital Universitario de Canarias (4)

2022

  1. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1